InsidersTradesSigma
Track the Instil Bio, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, Instil Bio, Inc. has published 2 insider filings. Market capitalisation: €50.3m. The latest transaction was disclosed on 12 September 2025 (Levée d'options). Among the most active insiders: Laumas Sandeep. All data is openly available.
2
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Instil Bio, Inc. Hold (neutral), based on 1 analysts. Average price target: US$7.00.
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 September 2025
Declarations2 total
17,000 shares@ US$11.60100.0% of flowCommon StockSEC:0001789769-25-000087:0
260,323 shares0Common StockSEC:0001567619-22-007150:0
2 of 2 declarations
About Instil Bio, Inc.
Instil Bio, Inc. is a biopharmaceutical company focused on developing cell therapies for cancer treatment. It utilizes advanced technologies to create innovative and personalized therapies.